Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACCP on cough

This article was originally published in The Tan Sheet

Executive Summary

The American College of Chest Physicians "uses the most rigorous and current methods to develop its evidence-based clinical practice guidelines, including those for cough," Richard Irwin, Chairman of ACCP's Cough Guidelines Committee, et al., state in a letter to The Lancet March 25. The group responds to a January editorial, which said ACCP cough treatment guidelines "may be a hollow exercise." ACCP said there was no evidence that OTC expectorants or suppressants relieve cough (1"The Tan Sheet" Jan. 16, 2006, p. 4). According to The Lancet, over half of the guidelines are "based more on opinion that on evidence," and one third are "based on 'low' evidence, yet backed with the second highest grade (B) of support." In response, Irwin et al. assert that the guide is "based on the best available evidence" and that when evidence was not robust, "the panel had to decide whether to do nothing or to offer some guidance to clinicians faced with patients in need of medical management." Where no published clinical trial results existed, panel members provided guidance and guidelines were graded with an "E" for "expert" in order to be "totally transparent," Irwin et al. say...

You may also be interested in...

Most OTC Cough Meds Dismissed By Chest Physicians Guidelines

The only effective OTC treatments for acute cough due to the common cold are older antihistamine/ decongestant products such as Wyeth's Dimetapp, according to revised guidelines issued by the American College of Chest Physicians

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts